12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Forma Therapeutics, Tgen deal

Forma and the institute's TGen Drug Development (TD2) cancer drug development subsidiary partnered to jointly develop small molecule cancer therapies. The partners said TD2 will bring...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >